# Dr Reddy's Gets DCGI Approval for Zytorvi

> Dr Reddy's Laboratories receives DCGI nod for Zytorvi immunotherapy in advanced esophageal cancer.
- Title: Dr Reddy's Gets DCGI Approval for Zytorvi · The Economic Times
- Summary: Dr Reddy's Laboratories receives DCGI nod for Zytorvi immunotherapy in advanced esophageal cancer. Dr Reddy's Laboratories gained DCGI approval for Zytorvi…
- Keywords: dr reddy's laboratories, zytorvi, esophageal cancer, immunotherapy, toripalimab, advanced esophageal squamous cell carcin, dcgi approval, Reddy's, Gets, DCGI, Approval, The Economic Times
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/dr-reddys-gets-dcgi-nod-for-zytorvi-in-advanced-esophageal-cancer/articleshow/135083439.cms
- Author: PTI
- Published: 2026-10-21T05:52:00+00:00
- Read time: 1 min
- Topics: dr reddy's laboratories, zytorvi, esophageal cancer, immunotherapy, toripalimab, advanced esophageal squamous cell carcin, dcgi approval
## DCGI Approval for Zytorvi
Dr Reddy's Laboratories received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.
## Second Approved Indication
Zytorvi is the second approved indication in India, expanding beyond nasopharyngeal carcinoma.
## ESCC Accounts for 80% of Cases
Advanced esophageal squamous cell carcinoma accounts for approximately 80 per cent of all esophageal cancer cases in India.
## Phase 3 Trial Results
The Phase 3 JUPITER-06 trial showed Zytorvi reduced disease or death risk by 42 per cent compared with chemotherapy alone.
## Key takeaway

Dr Reddy's Laboratories gained DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.